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We investigated the serum concentration of total metalloproteinase-9 (tMPP-9), active MMP-9 (aMMP-9), and tissue inhibitor of
metalloproteinase-1 (TIMP-1) in a group of 41 patients with SLE and 20 healthy controls. Serum levels of tMMP-9 and TIMP-1
wereassessedbyanenzyme-linkedimmunosorbentassay(ELISA)andaMMP-9byﬂuorometricassay.ThetMMP-9levelwaslower
in SLE patients (mean 262ng/mL) than in healthy volunteers (mean 325ng/mL) (P = .048). Similarly, aMMP-9 level was lower in
SLE patients (mean 121ng/mL) than in control group (mean 169ng/mL) (P = .0355) and lower in active SLE (mean 54ng/mL)
than in inactive disease (mean 99ng/mL) (P = .033). TIMP-1 level was also lower in SLE patients (mean 181ng/mL) than in
control group (mean 233ng/mL) (P = .004). In SLE patients, a positive correlation was found between tMMP-9 and aMMP-9
(ρ = 0.568; P = .001). We also found a positive correlation of tMMP-9 and TIMP-1 with VEGF concentrations (ρ = 0.450,
P = .005 and ρ = 0.387; P = .018, resp). tMMP-9, aMMP-9, and TIMP-1 serum levels are lower in SLE patients than in healthy
control group.
Copyright © 2006 Ewa Robak et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune dis-
ease characterized by B-cell hyperactivity, the formation of
pathogenic autoantibodies, and highly varied clinical mani-
festations [1, 2]. Among organs and systems targeted in this
disease the skin, joints, kidneys, nervous system, serosal sur-
faces, and blood cells are the most common sites of involve-
ment.
The involvement of angiogenesis and angiogenic factors
inpathogenesisofSLEhasbeenrecentlysuggested[3–6].An-
giogenesis is a multistep process in which new blood vessels
grow from existing vessels [7]. Extracellular matrix remod-
eling, endothelial cell migration and proliferation, capillary
diﬀerentiation and anastomosis are the sequential steps re-
quired for angiogenesis. A family of pro- and antiagiogenic
factors tightly regulates this process. A large number of cy-
tokineshavebeenshowntostimulateangiogenesis,including
vascular endothelial growth factor(VEGF).
In addition to growth factors and cytokines, extracellu-
lar matrix components such as matrix metalloproteinases
(MMP) have been implicated in angiogenesis [8]. Among
them MMP-2 and MMP-9, also called gelatinases A and
B, are reported to cleave a wide variety of substrates, al-
though their primary substrates are considered to be gelatin.
MMP-9 is also involved in inﬂammation and immune sys-
tem dysfunctions [9, 10]. MMP-9 originates from mono-
cytes, macrophages, neutrophils, keratinocytes, ﬁbroblasts,
endothelial cells, and various tumor cells. It is secreted in the
form of latent 92kd zymogens that need to undergo prote-
olytic and autocatalytic activation to 82kd form [11].
MMPs are inhibited by speciﬁc proteins—the tissue in-
hibitors of metalloproteinases (TIMP) [12]. TIMP-1 is one
of the four natural inhibitors of MMPs. It is a 28.5kd gly-
coprotein that forms a noncovalent 1:1 stoichiometric com-
plex with MMPs, thereby inhibiting the proteolytic activ-
ity of these enezymes [12]. TIMP-1 binds with high aﬃn-
ity to the inactive pro-MMP-9 forming a complex in which2 Mediators of Inﬂammation
Table 1: Clinical and laboratory characteristics of SLE patients.
Symptoms Number of patients (%)
Total 41 100%
Age (years)
Mean (range) 40.5 (19–73) —
Sex (male/female) 3/38 7%/93%
Active/inactive 19/22 46%/54%
Arthritis 34 83%
Skin symptoms 32 78%
Reticuloendothelial system involvement 23 56%
Renal disorder (kreatinine > 1.3mg/dL) 4 40%
Neurologic symptoms 27 66%
Antinuclear antibodies titer > 160 38 93%
dsDNA antibodies 6 15%
Anemia (Hb < 12g/dL) 18 44%
Leukopenia (WBC < 3.5 ×109/L) 14 34%
Thrombocytopenia (platelets < 150 ×109/L) 12 29%
C reactive protein (> 5.99mg/L) 4 10%
Raised ESR (> 25mm/h) 20 49%
C3 < 0.9 12 29%
C4 < 0.1 5 12%
Immunosuppressive treatment with steroid and/or cytotoxic 25 61%
agents during the study
TIMP-1 retains its ability to inhibit the activity of another
MMP via its N-terminal domain. Some physiological func-
tions of TIMP-1 are linked to the functions of MMP and an
improperbalanceintheirproductionsmayhavearoleinsev-
eral diseases including cancer and rheumatoid arthritis [13].
Moreover TIMP-1 inhibits apoptosis of B-cells [14].
MMPs and their inhibitors may play a role in pathogene-
sis of SLE and other connective tissue diseases [9, 14–20]. In
the present study we measured the serum concentrations of
total and active MMP-9 as well as TIMP-1 in patients with
SLE. The serum levels of these proteins were correlated with
disease activity and some clinical and laboratory parameters.
To the best of our knowledge a simultaneous evaluation of
these proteins in patients with SLE has not been investigated
to date.
PATIENTS AND METHODS
The study group consisted of 41 patients with SLE (38 fe-
males and 3 males) and 20 sex- and age-matched healthy
volunteers. The median age of SLE patients was 40.5years
(range 19–73) and 38years (range 16–68) in control group.
The diagnosis of SLE was based on the revised criteria of
the American Rheumatism Associaton [21]. Twenty-ﬁve pa-
tients were treated with steroids and/or other immunosup-
pressive agents. In all patients the activity of the disease was
determined according to the systemic lupus activity measure
(SLAM) scale [22]. Each patient was examined on two sep-
arate occasions, 2–4 weeks apart. The system of SLAM in-
cludes24clinicalmanifestationsandeightlaboratoryparam-
eters. The maximum score in this system is 84 points. In our
group of patients, the number of points ranged from 9–25.
In the present study we considered a score of 0–15 points as
inactivediseaseandscoreover15pointsasactivediseases.By
this deﬁnition, active disease was found in 19 patients while
22 patients had inactive disease. The clinical and laboratory
features of SLE patients are presented in Table 1.
Each person underwent a thorough physical evaluation
by one of the authors (E. Robak). The patients with SLE and
controls showed no clinical signs of infection or neoplas-
tic disease and received neither antibiotics nor other med-
ications for at least 4 weeks prior to blood donation. This
project was performed in accordance with the Helsinki Dec-
laration.
An informed consent was obtained from all patients par-
ticipating in the study. The project was approved by the lo-
cal Ethics Committee (Medical University of Lodz, no RNN
25/05/KE).
Laboratorytests
On the day of blood sampling for MMP-9 and TIMP-1
the following laboratory parameters were analysed: complete
blood cell count, erythrocyte sedimentation rate (ESR), uri-
nalysis, blood urea, nitrogen and creatinine levels, ﬁbrinogen
level, partial thromboplastin time (PTT), liver function tests
(GOT, GPT, bilirubin), immunoglobulins (IgG, IgA, IgM)
complement(C3,C4),andanti-DNAantibodies(ANA).The
lupusbandtest(LBT)wasalsodetermined.ChestX-raysand
abdominal ultrasonography were performed in all patients.Ewa Robak et al 3
Table 2: Serum levels of VEGF, total and active metalloproteinase-9 (MMP-9), and TIMP-1 in patients with SLE and control group (mean
values of VEGF in pg/mL, metalloproteinase-9, and TIMP-1 in ng/mL).
Factor
All SLE Active SLE Inactive SLE Control group
Statistically signiﬁcant comparison n = 41 n = 19 n = 22 n = 20
(a) (b) (c) (d)
VEGF x ±s 285 ±333 253 ±234 312 ±404 208 ±163 —
MMP-9 total
x ±s 262±242 183±164 333±280 325±168
(a)–(d) P = .023
(b)–(c)–(d) P = .014
(b)–(c) P = .048
(b)–(d) P<. 001
MMP-9 active
x ±s 121 ±123 90 ±71 147 ±151 169 ±104
(a)–(d) P = .035
(b)–(c)–(d) P = .033
(b)–(d) P = .016
TIMP-1 x±s 181 ±67 193 ±72 170 ±61 233 ±64
(a)–(d) P = .004
(b)–(c)–(d) P = .038
(c)–(d) P = .002
SerumsamplingandMMP-9,TIMP-1,and
VEGFdetermination
Venous blood samples were collected at the time of clinical
assessment in pyrogen free tubes, allowed to dot at −4◦Cf o r
1 hour and centrifuged at 2000 for 10 minutes. The serum
obtained was divided into aliquots and stored at −25◦C until
assayed for MMP-9, TIMP-1, and VEGF.
The detection of the serum levels of total MMP-9, TIMP-
1, and VEGF was performed using ELISA sandwich kits em-
ploying human anti-MMP-9, anti-TIMP-1, and anti-VEGF
antibodies (R&D Systems, Inc, Minneapolis, MN) using
horse radish peroxidase detection in accordance with the
manufacturer’s instructions. The absorption was read at
492nm. The appropriate recombinant human cytokine was
used to generate the standard curve for each assay. The
concentration of cytokines in the samples was determined
by the interpolation from the standard curve. Standards as
well as samples were assayed as duplicates and the interas-
say variations were shown to be within the range given by
the manufacturer. This procedure has been described pre-
cisely in our previous work [23, 24]. The sensitivity limit for
VEGF was 5.0pg/mL, tMMP-9–0.156ng/mL, and TIMP-1–
0.08ng/mL.
The detection of the serum aMMP-9 level was performed
using ﬂuorometric assay designed to quantitatively measure
enzyme activity (R&D Systems, Inc). The Fluorokine E Ac-
tive MMP-9 kit is designed to measure the levels of endoge-
nous active MMP-9. All manufacturer’s instructions were
followed. As suggested 100-fold dilution of the serum with
Calibrator Diluent RD 5–24 was used. Standard MMP-9
samples were activated during the assay with the addition of
AMPA(p-aminophenylmercuricacetable).Astandardcurve
was generated for each set of samples assayed. The sensitivity
limit for this assay was 0.005ng/mL. The results of all pro-
teins’ measurements were presented in units recommended
by ELISA kit producer.
Statisticalanalysis
For the statistical analysis of the data the range of mea-
sured variable (minimum-maximum), the mean arithmetic
value (x), the median (Me), and the standard deviation (SD)
were calculated. The Shapiro-Wilk test was used to evaluate
the distribution. The mean values were compared using the
Kruskal-Wallis test and Mann-Whitney’s test. The correla-
tionbetweenfeatureswasevaluatedusingtheSpearmanrank
coeﬃcient ρ. Comparisons and correlations were considered
signiﬁcant when P<. 05.
RESULTS
TheserumlevelsoftMMP-9,aMMP-9,TIMP-1,andVEGF
In the group of 41 SLE patients, 19 were with active and 22
with inactive disease according to the Liang et al [22] scoring
system. The serum concentrations of total and active MMP-
9 and TIMP-1 were detectable in all SLE patients and in
healthy volunteers. The results are presented in Table 2.T h e
tMMP-9 level was higher (mean 262ng/mL) than aMMP-9
(mean 121ng/mL) in SLE patients (P = .001) and in con-
trol group (325ng/mL and 169ng/mL, resp, P = .001). The
level tMMP-9 was lower in SLE patients (mean 262ng/mL)
than in healthy volunteers (mean 325ng/mL) (P = .023).
TheconcentrationoftMMP-9waslowerinactiveSLE(mean
182.6ng/mL) than in inactive disease (mean 333ng/mL)
(P = .048). However, the levels of tMMP-9 in inactive SLE
andhealthypersonsweresimilar(P>. 05).Similarly,aMMP-
9 level was lower in SLE patients (mean 121ng/mL) than in
control group (mean 169ng/mL) (P = .035). Moreover, a
lower concentration of aMMP-9 was in active SLE than in
inactive disease (mean 54ng/mL and 99ng/mL, resp, P =
.033). TIMP-1 level was also lower in SLE patients (mean
181ng/mL) than in control group (mean 233ng/mL) (P =
.004). The levels of TIMP-1 in active and ininactive disease
were similar (P>. 05). Moreover, we found no statistically4 Mediators of Inﬂammation
signiﬁcant correlation between SLE activity score according
to the SLAM index and the level of tMMP-9 (ρ = 0.223;
P>. 05), aMMP-9 (ρ = 0.222, P>. 05), and TIMP-1
(ρ = 0.111; P>. 05).
The concentrations of VEGF in SLE patients and in con-
trol group were similar in this study (P>. 05) (Table 2).
Thecorrelationsbetweeninvestigatedproteins
A positive correlation was found between tMMP-9 and
aMMP-9 in SLE patients (ρ = 0.568; P = .001) (Figure 1).
However, the correlations of aMMP-9 with TIMP-1 and
tMMP-9 with TIMP-1 were not statistically signiﬁcant. We
analyzed the correlation between serum levels of tMMP-9,
aMMP-9, and TIMP-1 with VEGF (Figure 2). We found a
positive correlation of VEGF with tMMP-9 (ρ = 0.450; P =
.005) and with TIMP-1 (ρ = 0.387; P = 0.018), but not with
aMMP-9 (ρ = 0.022, P>. 05).
Thecorrelationsofinvestigatedproteinswith
clinicalandlaboratoryparameters
In this study we compared the serum levels of tMMP-9,
aMMP-9, and TIMP-1 with several clinical and laboratory
symptoms of the disease. However the diﬀerences were not
statistically signiﬁcant, except for a higher level of tMMP-9
in patients without antinuclear antibodies (440ng/mL) than
in the patients with titer of antinuclear antibodies >160
(145ng/mL) (P = .003). The concentrations of these pro-
teins were also similar in the patients treated and untreated
with steroids and/or cytotoxic agents (data not shown).
DISCUSSION
The aim of our study was to assess serum concentrations of
total and active MMP-9 and its tissue inhibitor (TIMP-1) in
patients with active and inactive SLE and in healthy volun-
teers. Detectable concentrations of these factors were found
either in all patients with SLE and all healthy volunteers.
However, the concentrations of tMMP-9 and aMMP-9 were
unexpectedly lower in patients with SLE as compared with
control groups. Moreover, lower concentration of tMMP-9
was detected in patients with active SLE as compared with
patients with inactive disease.
The sparse data from literature concerning serum MMP-
9 concentration in patients with SLE are heterogeneous.
Faber-Elmann et al [19] found the increased activity of
MMP-9inserumofpatientswithSLE.However,Chineseau-
thors, similarly to our research, found lower levels of MMP-
9 in patients with SLE in comparison with healthy subjects
[25]. Besides, they observed lower concentration of MMP-9
in serum of patients with active SLE as compared with inac-
tive disease, similarly as in our patients. These scientists did
not report, however, what type of MMP-9 was determined.
In our research we did not ﬁnd any correlation between the
SLE activity according to the SLAM scale and tMMP-9 or
aMMP-9 concentrations. These observations are consistent
with results described by Faber-Elmann et al [19], who also
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Figure 1: Correlations between total and active MMP-9 in SLE pa-
tients.
did not demonstrate any correlation between serum MMP-9
level and the Systemic Lupus Erythematosus Disease Activity
Index.
A signiﬁcant part of our research was to assess a correla-
tion between the presence or absence of clinical and labora-
tory SLE symptoms and serum tMMP-9 and aMMP-9 levels.
This research did not show any statistically signiﬁcant corre-
lations between concentrations of these factors and the pres-
ence of any clinical or laboratory symptoms, except the pres-
ence of antinuclear antibodies. However, a lack of statistical
signiﬁcance can result from the small number of patients in
the given groups. Makowski and Ramsby [15] examined a
correlation between MMP-9 concentration and anti-sDNA
or anti-dsDNA levels showing reverse correlation with anti-
dsDNA, which is a speciﬁc marker of SLE. Similarly, Liu et
al [25] observed lower concentration of MMP in patients
with lupus nephritis as compared with patients with SLE
without renal impairment. These observations are consistent
in patients with active SLE as compared with patients with
inactive disease.
LowerconcentrationofMMP-9inserumofpatientswith
SLE, especially with active disease detected either in our re-
search or in studies performed by other authors bring to
mind some interpretative diﬃculties. It was found that the
peripheralbloodmononuclearcells(PBMC)inpatientswith
SLE form and secrete more MMP-9 than their counterparts
in healthy volunteers [9]. Moreover, the most increased pro-
MMP-9activityinsidethePBMCswasidentiﬁedforrelapsed
SLE subgroup. It can be assumed that in SLE, more MMP-
9 is transported from blood to the lupoid tissues, especially
blood vessels in the more active SLE patients. Mawrin et
al [17] showed that in patients with SLE and peripheral neu-
ropathy, MMP-3 and MMP-9 can be detected in vessel walls
of nerves when in healthy subjects they were not found.Ewa Robak et al 5
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Figure 2: Correlations between VEGF and MMP-9 total, MMP-9 active, and TIMP-1 serum levels.
The authors suggest that up-regulation of MMP-3 and
MMP-9 within the vessels may be responsible for vascular
damage seen in SLE.
To date even less attention has been paid to the role of
TIMP-1 in patients with SLE in comparison with MMP-9.
According to our knowledge our research is the ﬁrst in which
this factor was determined in serum of patients with SLE.
In our studies TIMP-1 concentration, similarly as MMP-9,
was lower in patients with SLE than in healthy volunteers.
M a t a c h ee ta l[ 9] did not ﬁnd any signiﬁcant diﬀerences in
the formation of this protein by leukocytes in patients with
SLE and in healthy subjects, however higher amounts were
formed in leukocytes of patients with more active SLE. How-
ever, we did not ﬁnd signiﬁcant diﬀerences in this cytokine
concentration in patients with active and inactive SLE, and
in patients with various clinical and laboratory symptoms
of this disease. These results are diﬀerent from those ob-
tainedbyToubietal[20]inpatientswithscleroderma.Inthis
pathology of connective tissue, the concentration of TIMP-1
was higher as compared with healthy volunteers and corre-
lated with the severity of scleroderma. Similar correlations
between serum TIMP-1 concentrations were observed by
Tayebjee et al [26], in patients with angiographically proven
peripheral arterial disease, in which TIMP-1 concentration
also correlated with the severity of clinical symptoms.
In our studies we did not show any correlations between
serumTIMP-1concentrationandtMMP-9andaMMP-9lev-
els. However, this correlation was observed by some authors
in healthy controls [27]. In our studies we showed the pos-
itive correlation between concentrations of tMMP, TIMP-1,6 Mediators of Inﬂammation
and VEGF. These results can be at least partially explained
by the fact that the above-mentioned agents are prerequisite
factors for angiogenesis.
To summarize, we have concluded that in patients with
SLE, serum tMMP-9, aMMP-9, and TIMP-1 levels are lower
as compared with healthy volunteers. The levels of these fac-
tors do not correlate with the activity of SLE according to the
SLAM classiﬁcation, or with the presence of particular clin-
ical and laboratory symptoms of SLE. Moreover, we showed
a positive correlation between tMMP-9, TIMP-1, and VEGF
concentrations in sera of patients with SLE. Lower concen-
trations of MMP-9 and TIMP-1 in patients with SLE can re-
sult from the accumulation of these factors in the inﬂamed
blood vessels and tissues.
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